HHHBIO
LIVE

Serial Number

79300811

Owner

3H Bio. Co., Ltd.

Attorney

Paul G. Johnson

Filing Date

Jul 10, 2020

Add to watchlist:

No watchlists yet
View on USPTO

HHHBIO Trademark

Serial Number: 79300811 • Registration: 6399124

HHHBIO is a trademark filed by 3H Bio. Co., Ltd. on July 10, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

3H Bio. Co., Ltd.

2F A8, 165, Yeoksam-ro,

Entity Type: 16

Trademark Details

Filing Date

July 10, 2020

Registration Date

June 29, 2021

Published for Opposition

April 13, 2021

Goods & Services

Drugs for medical purposes, namely, drugs for the treatment of oncological and metabolic diseases and disorders; medicines for human purposes, namely, medicine for the treatment of infectious diseases; medicines for human purposes, namely, medicine for the treatment of viral diseases and disorders; medicines for human purposes, namely, medicine for the treatment of respiratory diseases and disorders; therapeutic drugs and agents, namely, therapeutic drugs for the treatment of immune system related diseases and disorders; pharmaceutical preparations for preventing and treating obesity; vaccines; human vaccine preparations; pharmaceutical agents affecting metabolism; protein for medical purposes, namely, protein arrays for diagnosing cancer; protein for medical purposes, namely, protein arrays for diagnosing allergies; peptide for medical purposes, namely, synthetic peptides for the treatment of immune system related diseases and disorders; synthetic protein for the treatment of diabetes; synthetic protein for the treatment of oncological and metabolic diseases and disorders; synthetic peptide for the treatment of obesity; synthetic peptide for the treatment of viral diseases and disorders; pharmaceutical preparations containing peptides as the active ingredients, namely, pharmaceutical preparations for the treatment of neurological diseases and disorders

Research relating to pharmaceuticals, namely, pharmaceutical research services; medicine research, namely, research and development of medicines; medical analysis services of peptide for the treatment of people; research for medical products, namely medical research; chemical research; biological research; laboratory research in the field of pharmaceuticals; clinical studies of medicines, namely, conducting clinical trials for others; operation of medical laboratory, namely, medical laboratory services; scientific research for medical purposes; research and development of peptide for medical purposes; research of biology; research and development of peptide for scientific or laboratory purposes; drug discovery services; research and development of technology for biotechnology; development of pharmaceutical preparations and medicines

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Jan 28, 2022 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 23, 2021 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Oct 28, 2021 FICS
FINAL DISPOSITION PROCESSED
Oct 28, 2021 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 29, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Jun 29, 2021 R.PR
NOTIFICATION PROCESSED BY IB
Apr 13, 2021 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 13, 2021 NPUB
PUBLISHED FOR OPPOSITION
Apr 13, 2021 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 24, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 24, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 24, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 11, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 10, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 9, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 9, 2021 TROA
REFUSAL PROCESSED BY IB
Mar 1, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 5, 2021 RFCS
REFUSAL PROCESSED BY MPU
Feb 5, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 20, 2021 RFCR
NON-FINAL ACTION WRITTEN
Jan 19, 2021 CNRT
APPLICATION FILING RECEIPT MAILED
Jan 16, 2021 MAFR
ASSIGNED TO EXAMINER
Jan 12, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 12, 2021 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jan 11, 2021 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 24, 2020 REPR